GC Biopharma will acquire ABO Holdings for $96 million to enhance its immunoglobulin medication Alyglo's supply chain.
The company's plant in Ochang, North Chungcheong is buzzing with the production of the blood product, the first by a Korean pharmaceutical to secure FDA approval.
The U.S. FDA approved GC Biopharma's blood product Alyglo, making the drug the first domestically developed blood product to enter the U.S. market.
Korea JoongAng Daily Sitemap
